Last updated on April 2018

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma


Brief description of study

TITAN RCC (0216-ASG) is a Phase 2, open-label study of nivolumab monotherapy with additional nivolumab/ipilimumab "boost" cycles in previously untreated and pretreated (2nd line), advanced or metastatic renal cell carcinoma (mRCC) subjects with intermediate and high risk disease according to IMDC.

Detailed Study Description

The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal cell carcinoma (RCC) with clear cell component

Clinical Study Identifier: NCT02917772

Contact Investigators or Research Sites near you

Start Over

Marc-Oliver Grimm, Prof. Dr.

Universit tsklinikum Jena und Poliklinik f r Urologie
Jena, Germany
  Connect »

Aysun Karatas, Dr.

Charit Universit tsmedizin Berlin
Berlin, Germany
  Connect »

Aysun Karatas, Dr.

Ordensklinikum Linz Barmherzige Schwestern
Linz, Austria
  Connect »

Aysun Karatas, Dr.

AKH Wien Universit tsklinik f r Innere Medizin I
Wien, Austria
  Connect »

Aysun Karatas, Dr.

ZNA Middelheim
Antwerpen, Belgium
  Connect »

Aysun Karatas, Dr.

CHR Verviers
Verviers, Belgium
  Connect »

Aysun Karatas, Dr.

Fakultn nemocnice Hradec Kr lov
Hradec Králové, Czechia
  Connect »

Aysun Karatas, Dr.

Fakultn nemocnice Olomouc
Olomouc, Czechia
  Connect »

Aysun Karatas, Dr.

FN Motol
Praha, Czechia
  Connect »

Aysun Karatas, Dr.

V eobecn fakultn nemocnice
Praha, Czechia
  Connect »

Aysun Karatas, Dr.

CHD Vend e
La Roche-Sur-Yon, France
  Connect »

Aysun Karatas, Dr.

Centre H pitalier Lyon Sud
Lyon, France
  Connect »

Aysun Karatas, Dr.

H pitaux Universitaires de Strasbourg H pital Civil
Strasbourg, France
  Connect »

Aysun Karatas, Dr.

Institut Claudius Regaud
Toulouse, France
  Connect »

Aysun Karatas, Dr.

Institut Gustave Roussy
Villejuif, France
  Connect »

Aysun Karatas, Dr.

Universit tsklinikum Carl Gustav Carus
Dresden, Germany
  Connect »

Aysun Karatas, Dr.

Universit tsklinikum D sseldorf
Düsseldorf, Germany
  Connect »

Aysun Karatas, Dr.

Universit tsklinikum
Düsseldorf, Germany
  Connect »

Aysun Karatas, Dr.

Universit t des Saarlandes Medizinische Fakult t
Homburg/Saar, Germany
  Connect »

Aysun Karatas, Dr.

Azienda USL8 Arezzo U.O.C. Oncologia Medica
Arezzo, Italy
  Connect »

Aysun Karatas, Dr.

Fondazione IRCCS Istituto Nazionale dei Tumori
Milano, Italy
  Connect »

Aysun Karatas, Dr.

IRCCS Fondazione Policlinico San Matteo
Pavia, Italy
  Connect »

Aysun Karatas, Dr.

Azienda Ospedaliera San Camillo Forlanini
Roma, Italy
  Connect »

Aysun Karatas, Dr.

Policlinico Universitario A. Gemelli
Roma, Italy
  Connect »

Aysun Karatas, Dr.

Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
  Connect »

Aysun Karatas, Dr.

Hospital 12 de Octubre
Madrid, Spain
  Connect »

Aysun Karatas, Dr.

Hospital Ram n y Cajal
Madrid, Spain
  Connect »

Aysun Karatas, Dr.

Hospital Universitario Central de Asturias
Oviedo, Spain
  Connect »

Aysun Karatas, Dr.

Complejo Hospitalario de Navarra
Pamplona, Spain
  Connect »

Aysun Karatas, Dr.

Hospital Universitario Marques de Valdecilla
Santander, Spain
  Connect »

Aysun Karatas, Dr.

Hospital Virgen del Rocio
Sevilla, Spain
  Connect »

Aysun Karatas, Dr.

Broomfield Hospital
Chelmsford, United Kingdom
  Connect »

Aysun Karatas, Dr.

Charing Cross Hospital
London, United Kingdom
  Connect »

Aysun Karatas, Dr.

Kent Oncology Centre
Maidstone, United Kingdom
  Connect »

Aysun Karatas, Dr.

Royal Preston Hospital
Preston, United Kingdom
  Connect »